Neuroimmunomodulation in Immune Privilege: Role of Neuropeptides in Ocular Immunosuppression

NeuroImmunoModulation

Volumn 3, Issue 4, 1996, Pages 195-204

  Taylor, Andrew W ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Eye; Immune privilege; Immunosuppression; Neuropeptides; T lymphocytes; Vasoactive intestinal peptide; Melanocyte stimulating hormone

Indexed keywords

CYTOKINE; NEUROPEPTIDE;

ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; BRAIN; CEREBROSPINAL FLUID; EYE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ADAPTATION, PHYSIOLOGICAL; ADJUVANTS, IMMUNOLOGIC; EYE; HUMANS; IMMUNOSUPPRESSION; NEUROIMMUNOMODULATION; NEUROPEPTIDES;

EID: 12644312226     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000097271     Document Type: Article

References (101)

1. Hubbard RD, Flory CM, Collins FM: Memory T cell-mediated rcsislancc lo Mycobacterium tuberculosis infcclion in innately susceptible and resistant mice, Infect Immun 1991:59: 2012-2016.
2. Slier A, Coffman RL: Regulation of immunity to parasites by T cells and T cell-derived cytokines, Annu Rev Immunol 1992;10:385-409.
3. Thierry B, Ccrotlini JC, Van den Eynde B, Van dcr Bruggcn P, Van Pel A: Tumor antigens recognized by T lymphocytes, Annu Rev Immunol 1994;12:337-365.
4. Rosenberg AS, Singer A: Cellular basis of skin allograft rejection: An in vivo model of im-munc-mediatcd tissue destruction, Annu Rev Immunol 1992;10:333-358.
5. Martin R, McFarland HF, McFarlin DE: Immunological aspects of demyelinating diseases, Annu Rev Immunol 1992;10:153-187.
6. Caspi RR, Roberge FG, McAllister GG, El Said M, Kmvabara T, Gery I, Hanna E, Nus-senblatt RB: T cell lines mediating experimental autoimmune uveoretinitis in the rat, J Immunol 1986;136:928-933.
7. Jorgensen JL, Rcay PA, Ehrich EW, Davis MM: Molecular components of T-cell recognition, Annu Rev Immunol 1992;10:835-873.
8. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor family, Immunol Today 1994;15:321-331.
9. Liu Y, Linslcy PS: Costimulation of T-cell growth, CurrOpin Immunol 1992;4:265-270.
10. Schmitt E, Van Brandwijk R, Fischer H-G, Rude E: Establishment of different T cell sub-types using either interleukin 2 or interleukin 4 as growth factors, Eur J Immunol 1990;20: 1709-1715.
11. Trinchieri G: Interleukin-12 and its role in the generation of Thl cells, Immunol Today 1993; 14:335-338.
12. Fong TAT, Mosmann TR: The role of IFN-y in delayed-type hypersensitivity mediated by Th I clones, J Immunol 1989,143:2887-2893.
13. Cher DJ, Mosmann TR: Two types of murine helper T cell clone, II, Delayed-type hypersensitivity is mediated by Thl clones, J Immunol 1987;138:3688-3694.
14. Trincheri G, Perussia B: Immune interferon: A pleiotropic lymphokine with multiple cficcts, ImmunoIToday 1985;6:131-136.
15. Farrar MA, Schreiber RD: The molecular cell biology of interferon-Y and its receptor, Annu Rev Immunol 1993; 11:571-611.
16. Dvorak HF, Mihm MC, Dvorak AM, Johnson RA, Manseau EJ, Morgan E, Colvin RB: Morphology of delayed type hypersensitivity reactions in man, I, Quantitative description of the inflammatory response, Lab Invest 1974,31: 111-130.
17. Bennett NT, Schultz GS: Growth factors and wound healing: Biochemical properties of growth factors and their receptors, Am J Surg 1993:165:728-737.
18. Andersen IH, Marker O, Thomsen AR: Breakdown of blood-brain barrier function in the murine lymphocytic choriomeningitis virus infection mediated by virus-specific CD8+ T cclls, J Ncuroimmunol 1991:31:155—163.
19. Niederkom JY, Shadduck JA, Steilcin JW: Im-munogenetic basis for immunologic privilege in the anterior chamber of the eye, Immunogc-netics 1981:13:227-236.
20. Streilein JW: Ocular immune privilege in the immunosuppressive intraocular microenvironment, Ocul Immunol Inflamm 1995;3:139-143.
21. Taylor AW: lmmunorcgulalion of the ocular effector responses by soluble factors in aqueous humor, Reg Immunol 1994:6:52-57.
22. Streilein JW, Wilbanks GA, Taylor AW, Cousins S: Eye-derived cytokines and the immunosuppressive intraocular microenvironment: A review, CurrHyeRes 1992:11 (suppl):41-47.
23. Taylor A, Streilein J, Cousins S: Identification of alpha-mclanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor, Curr Eve Res 1992:11:1199-1206.
24. Taylor AW, Streilein JW, Cousins S\V: Immu-norcactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor, J Immunol 1994:153: 1080-1086.
25. Medawar P: Immunity to homologous grafted skin, III, The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye, Br J Exp Pathol 1948:29:58-69.
26. Barker CF, Billingham RE: lmmunologically privileged sites, Adv Immunol 1977:25:1-54.
27. Vinores SA: Assessment of blood-retinal barrier integrity, Histol Histopathol 1995:10:141-154.
28. Fabry Z, Raine CS, Hart MN: Nervous tissue as an immune compartment: The dialect of the immune response in the CNS, Immunol Today 1994;15:218-224.
29. Betz AL: An overview of the multiple functions of the blood-brain barrier, NIDA Res Monogr 1992;120:54-72.
30. Kaplan HJ, Streilein JW: Transplantation immunology of the anterior chamber of the eye, II, Immune response to allogeneic cclls, J Immunol 1975:115:805-810.
31. Bill A: The role of ciliary body flow and ultrafiltration in aqueous humor formation, Exp Eye Res 1973;16:287-299.
32. Cserr HF, Knopf PM: Cervical lymphatics, the blood-brain barrier and the immunorcactivity of the brain: A new view, Immunol Today 1992:13:507-512.
33. Cserr H: Physiology of the choroid plexus, Physiol Rev 1971;51:273-311.
34. McGahan MC, Hamcd J, Goralska M, Sherry B, Fleisher LN: Transferrin secretion by lens epithelial cclls in culture, Exp Eye Res 1995:60: 667-673.
35. Kaiser R, Lucking CH: Intrathecal synthesis of JgM and IgA in neurological diseases: Comparison of two formulae with isoclcctric focusing, Clin Cliim Acta 1993:216:39-51.
36. Schuller E, Gervais A, Rcboul J, Lebon P, Devillcchabrollc A, Huraux JM: Intrathecal synthesis of proteins: From immunoglobulins to prcalbumin, Ital J Neurol Sci 1992:13:69-77.
37. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apopto-sis as a mechanism of immune privilege, Science 1995:270:1189-1192.
38. Bellgrau D, Gold D, Sclawry H, Moore J, Fran-zusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection, Nature 1995:377: 630-632.
39. Brummer T, Mogil RJ, LaFacc D, Yoo NJ, Mahboubi A, Echcverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas(CD95)/Fas ligand interactions mediate activation-induced apoptosis in T-cell hvbridoma, Nature 1995:373:441-444.
40. Dhcin J, Walezak H, Baumler C, Debatin KM, Krammcr PH: Autocrine T-cell suicide mediated by APO-l/Fas(CD95), Nature 1995: 373:438-441.
41. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rolhstein A: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature 1995;373:444-448.
42. Lynch DH, Ramsdcll F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses, Immunol Today 1995;16:569-574.
43. Ehl S, Hoffmann-Rohrcr U, Nagata S, Ilcn-gartner H, Zinkcrnagel R: Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo, J Immunol 1996:156: 2357-2360.
44. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schoolev K, Ramsdcll F, Lynch DH: Fas transduces activation signals in normal human T Ivmphocytcs, J Exp Med 1993:178:223-2235.
45. Lai HT, Yu M, Fontana A, Stoeckert CJ: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice, Science 1996:273:109-112.
46. Hickey VV, Hsu B, Kimura H: T-lvmphocyte entry into the central nervous system, J Ncu-rosci Res 1991:28:254-260.
47. Kaiser C, Ksander B, Streilein J: Inhibition of lymphocyte proliferation by aqueous humor, Reg Immunol 1989:2:42-49.
48. Cousins SW, McCabc MM, Daniclpour D, Streilein JW: Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor, Invest Ophthalmol Vis Sci 1991;32:33-43.
49. Granstein R, Staszewski R, Knisely TL, Zcira E, Nazarcno R, Latina M, Albert DM: Aqueous humor contains transforming growth factor-p and a small (<3.500 daltons) inhibitor of thymocyte proliferation, J Immunol 1990:144: 3021-3026.
50. Taylor AW, Streilein JW: Inhibition of antigen-stimulated effector T cells by human cerebrospinal fluid, Ncuroimmunomodulation 1996: 2-3:112-118.
51. Wilson JF, Harry FM; Release, distribution and half-life of u-melanotrophin in the rat, Endocrinology 1980:86:61-67.
52. Cousins SW, Trattler WB, Streilein JW: Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye, Curr Eye Res 1991:10:287-297.
53. Jampel I ID, Roche N, Stark WJ, Roberts AB: Transforming growth factor-p in human aqueous humor, Curr Eye Res 1990:9:963-969.
54. Roberts AB, Sporn MB: Transforming growth factor [i, Adv Cancer Res 1988:51:107-145.
55. Miyazono K, Olofsson A, Colosctti P, Heldin CH: A role of the latent TGF-pi-binding protein in the assembly and secretion of TGF-pl, EM BO J 1991:10:1091-1101.
56. Flaumcnhafl R, Kojinia S, Abe M, Rifkm DB: Activation of latent transforming growth factor beta, Adv Pharmacol 1993:24:51-76.
57. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin C-H, Rifkin DB: Role of the latent TGF-P binding protein in the activation of latent TGF-P by coculturcs of endothelial and smooth muscle cells, J Cell Biol 1993:120: 995-1002.
58. Pasquale LR, Dorman-Pcasc ME, Lutty GA, Quigley I1A, Jampel 1ID: Immunoloealization ofTGF-PI, TGF-P2, and TGF-p3 in the anterior segment of the human eye, Invest Ophthalmol Vis Sci 1993:34:23-30.
59. Knisely TL, Blcichcr PA, Vibbard CA, Granstein RD: Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells, Curr Eye Res 1991:10:761-771.
60. Constant DB, Philipp J, Malipiero UV, Ten-Dijke P, Schachncr M, Fontana A: Differential expression of transforming growth factor-PI, -P2, and -P3 by glioblastoma cells, astrocytes, and microglia, J Immunol 1992:148:1404-1410.
61. Wilbanks GA, Streilein JW: Fluids from immune privileged sites endow macrophages w ith the capacity to inducc antigen-specific immune deviation via a mechanism involving transforming growth factor-p, Eur J Immunol 1992: 22:1031-1036.
62. Shull MM, Ormsby I, Kier AB, Pawlowski S, Dicbold RJ, Yin M, Allen R, Sidman C, Pro-ctzcl G, Calvin D, Annunziata N, Doelschman T: Targeted disruption of the mouse transforming growth factor-pi gene results in multifocal inflammatory disease, Nature 1992:359:693-699.
63. Goctzl EJ, Adclman DC, Srccdharan SP: Ncu-roimmunology, Adv Immunol 1990:48:161-190.
64. Mason MJ, Van Epps D: Modulation of IL-I, tumor necrosis factor, and C5A-mcdiated murine neutrophil migration by ci-melanocytc-stimulating hormone, J Immunol 1989:142: 1646-1651.
65. Holdcman M, Khorram O, Samson WK, Lip-1011 JM: Fever-specific changes in ccntr.il MSI I and CRF concentrations, Am J Physiol 1985; 248:R125-R129.
66. Watanabc T, Hilt/, ME, Catania A, Lipton JM: Inhibition of IL-lp-induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide u-MSH, Brain lies Bull 1993:32:311-314.
67. Martin LV, Catania A, Hiltz ME, Lipton JM: Neuropeptide alpha-MSH antagonizes IL-6-and TNF-induced fever, Pcplides 1991:12: 297-299.
68. Rhcins LA, Cotlcur AL, Kleiei RS, Hoppen-jans WB, Saundcr DN, Nordlund JJ: Alplia-mclanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice, J Invest Dermatol 1989:93: 511-517.
69. Mugridge KG, Perretti M, Gliiara P, Parentc L: u-Melanocytc-stimulating hormone reduces interleukin- I i effects on rat stomach preparations possibly through interference with type I receptor, EurJ Pharmacol 1991:197:151-155.
70. Lipton JM: Modulation of host defense by the neuropeptide a-MSH, Yale J Biol Med 1990: 63:173-182.
71. Cannon JG, Tatro JB, Reichlin S, Dinarcllo CA: u-Melanocyte stimulating hormone inhibits immunoslimulatorv and inflammatory actions of interleukin I, J Immunol 1986:137: 2232-2236.
72. Taylor AW, Strcilcin JW, Cousins SV: Alpha-inelanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gam-ma-interferon, Ncuroimmunomodulation 1994;1:188-194.
73. Parronchi P, Dc Carli M, Manctti R, Simonelli C, Sampognaro S, Piccinni M-P, Macchia D, Maggi E, Del Prete G, Romagnani S: IL-4 and IFN (a and y) exert opposite regulatory elTccts on the development of cytolytic potential by Thl and Th2 human T cell clones, J Immunol 1992:149:2977-2983.
74. Gautam S, Tebo JM, Hamilton TA: IL-4 suppresses cytokine expression induced by lFN-y and/or IL-2 in murine peritoneal macrophages, J Immunol 1992:148:1725-1730.
75. Finkclman FD, Katona IM, Urban JF, Snapper CM, Ohara J, Paul WE: Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokinc B-ccll stimulatory factor i, Proc Natl Acad Sci USA 1986:83:9675-9678.
76. Coffman RL, Ohara J, Bond MW, Cany J, Zlotni A, Paul WE: B cell stimulatory factor I enhances the IgE response of lipopolvsaccha-ride-activatcd B cells, J Immunol 1986; 136: 4538-4541.
77. Uddman R, Alumets J, Ehingcr B, Häkanson R, Loren I, Sundler F: Vasoactive intestinal peptide nerves in ocular and orbital structures of the cat, Invest Ophthalmol Vis Sci 1980:19: S78-885.
78. Musccttola M, Grasso G: Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells, Immunobiology 1990:180: 419-430.
79. O'Dorisio MS, Wood CL, O'Dorisio TM: Vasoactive intestinal peptide and neuropeptide modulation of the immune response, J Immunol 1985:135(suppl):792-796.
80. Stanisz AM, Scicchitano R, Bienenstock J: The role of vasoactive intestinal peptide and other neuropeptides in the regulation of the immune response in vitro and in vivo, Ann NY Acad Sci 1988:527:478-455.
81. Oltaway CA: Vasoactive intestinal peptide as a modulator of lymphocyte and immune function, Ann NY Acad Sci 1988;527:486-500.
82. Tseng J, O'Dorisio MS: Mechanism of vasoactive intestinal peptide (VlP)-mediated imniu-noregulation: in Goctzl EJ, Spector NH (eds): Ncuroimmunc Networks: Physiology and Diseases, New York, Liss, 1989, pp 105-111.
83. Boudard F, Bastide M: Inhibition of mouse T-cell proliferation by CGRP and VIP: Effects of these neuropeptides on IL-2 production and cAMP synthesis, J Ncurosci Res 1991:29:29-41.
84. Ganea D, Sun L: Vasoactive intestinal peptide downregulatcs the expression of IL-2 but nol of IFN-y from stimulated murine T lymphocytes, J Ncuroimmunol 1993:47:147-158.
85. Beckers H, Klooster J, Vrensen G, Lamers W: Substance P in the rat comcy and iridial nerves: An ultrastructural immunohistochemi-cal study, Ophthalmic Res 1993:25:192.
86. Unger WG, Butler JM, Cole DF, Bloom SR, McGregor GP: Substance P, vasoactive intestinal peptide (VIP) and somatostatin levels in ocular tissue of normal and sensorilv dcner-vated rabbit eyes, Exp Eye Res 1981:32:797-801.
87. Wahlestedt C, Beding B, Ekman R, Oksala O, Stjcrnschantz J, IIäkanson R: Calcitonin gene-related peptide in the eye: Release by sensory nerve stimulation and effects associated with neurogenic inflammation, Rcgul Pepl 1986:16: 107-115.
88. Nicolai J, Larsen B, Bersani M, Olcese J, Holst JJ, Möller M: Somatostatin and prosomatostatin in the retina of the rat: An immunohisto-chcmical, in situ hybridization, and chromatographic study, Vis Ncurosci 1990:5:441-452.
89. Terenghi G, Polak JM, Gliatci MA, Mulderry PK, Butler JM, Unger WG, Bloom SR: Distribution and origin of calcitonin gene-related peptide (CGRP) immunoreactivity in the sensory innervation of the mammalian eye, J Comp Neurol 1985:233:506-516.
90. Asahina A, Hosoi J, Biessct S, Stratigos A, Granstein RD: Inhibition of the induction of delaycd-tvpe and contact hypersensitivity by calcitonin gene-related peptide, J Immunol 1995:154:3056-3061.
91. Ferguson TA, Fletcher S, Herndon J, Griffith TS: Neuropeptides modulate immune deviation induced via the anterior chamber of the eye, J Immunol 1995:155:1746-1756.
92. Kniscly TL, Hosoi J, Nazarcno R, Grandstein RD: The presence of biologically significant concentrations of glucocorticoids but little or 110 cortisol binding globulin with aqueous humor: Relevance to immune privilege in the anterior chamber of the eye, Invest Ophthalmol Vis Sci 1994:35:3711-3723.
93. Benson JL, Niederkorn JY: In situ suppression of delaycd-tvpe hypersensitivity: Another mechanism for sustaining the immune privilege of the anterior chamber, Immunology 1991:74:153-159.
94. Wisniewski HM, Bloom BR: Primary demy-clination as a nonspecific consequence of a cell-mediated immune reaction, J Exp Med 1975:142:346-359.
95. Ncilson EG, Jimenez SA, Phillips SM: Cell mediated immunity in interstitial nephritis, 3, T lymphocytc-mcdiatcd fibroblast proliferation and collagen synthesis: An mmune mechanism for renal fibrogcncsis, J Immunol 1980;125:1708-1714.
96. Kimura R, Hu H, Stcin-Strcilein J: Delayed-lvpe hypersensitivity responses regulate collagen deposition in the lung, Immunology 1992:77:550-555.
97. Chen Y, Kuchroo VK, Inobe JI, Haller DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis, Science 1994:265: 1237-1240.
98. Karpus WJ, Swanborg RH: CD4+ suppressor cells inhibit the function of effector cclls of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-5, J Immunol 1991; 146:1163-1168.
99. Gcry I, Strcilcin JW: Autoimmunity in the eye and its regulation, Curr Opin Immunol 1994;6:938-945.
100. Zierhut M, Hcmandy R, Zhao TZ, Merchant A, Foster CS: Herpes simplex virus type 2 induced retinal necrosis in BALB/c mice, Acta Ophthalmol (Copcnh) 1994:72:211-217.
101. Steward JF, Croxson MC, Powell KF, Pol-kinghome PJ: Identification of cytomegalovirus in vitreous using polymerase chain reaction, Aust NZ J Ophthalmol 1993.21:165-169.